Exabis Library
Welcome to the e-CCO Library!
DOP79: Alternative polygenic forms of Inflammatory Bowel Disease are not captured by current generations of polygenic risk scores
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP79: Biomarkers for IBD using OLINK Proteomics inflammation panel: Preliminary results from the COLLIBRI consortium
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP79: Effect of vedolizumab on surgical rates in IBD: post hoc analysis from the GEMINI trials
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP79: Primary hypogammaglobulinemia with IBD-like features: An ECCO CONFER Multicenter Case Series
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP80 Effectiveness of ustekinumab and vedolizumab in patients with Crohn’s disease refractory to anti-tumour necrosis factor: A multi-centre comparative study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP80: Automatic detection of ulcers and erosions in PillCam™ Crohn’s capsule using a convolutional neural network
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP80: Integrated tissue transcriptomic and serum proteomic interrogation reveals biomarkers for endoscopic improvement and histologic remission after JAK3/TEC inhibition with ritlecitinib (PF-06651600) in Ulcerative Colitis (UC) (Phase 2b Vibrato study)
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP80: Multi-omic sequencing reveals distinctive gene expression and DNA methylation alterations as potential predictors of primary sclerosing cholangitis development in treatment-naïve paediatric ulcerative colitis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP80: Oral curcumin is not more effective than placebo to prevent endoscopic postoperative recurrence in patients with Crohn's disease treated with concomitant thiopurines: the POPCUR trial
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP81 Time to loss of efficacy among patients in remission following induction treatment with tofacitinib 10 mg BID who reduced tofacitinib dose or discontinued tofacitinib in OCTAVE sustain
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP81: Baseline whole-blood gene expression of TREM1 does not predict clinical or endoscopic outcomes following adalimumab treatment in patients with Ulcerative Colitis or Crohn’s Disease in the SERENE studies
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP81: Quality improvement by semi-automated benchmarking of a core outcome quality indicator set in Inflammatory Bowel Disease: A multicentric feasibility study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP81: Unaffected ileal transcriptomics in Crohn's disease is associated with the response to anti-TNF therapy
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP81: Utility of a simple blood test for mucosal healing monitoring is accurate in post-operative Crohn’s disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP82 Macrophages in Crohn’s disease mesentery are predominantly inflammatory and produce calprotectin
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP82: Achievement of steroid-free remission in patients with moderately to severely active Crohn’s Disease during treatment with risankizumab
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP82: Biological Treatment Cycles in Crohn's Disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP82: Corticosteroid-free remission of Ulcerative Colitis with filgotinib maintenance therapy: Post hoc analysis of the phase 2b/3 SELECTION study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP82: Direct and indirect costs of inflammatory bowel disease in the biological era; 10 years of follow-up in a Danish population-based inception cohort
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP83 Intestinal fibrosis in Crohn’s disease patients is marked by up-regulation of innate immune cells and mucosal B cells
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM